[EN] SMALL MOLECULE CMKLR1 ANTAGONISTS IN DEMYELINATING DISEASE<br/>[FR] ANTAGONISTES CMKLR1 À PETITES MOLÉCULES POUR MALADIE DÉMYÉLINISANTES
申请人:UNIV LELAND STANFORD JUNIOR
公开号:WO2013109543A1
公开(公告)日:2013-07-25
Compounds and methods are provided for decreasing demyelinating inflammatory disease in a subject by inhibiting the activity of chemokine-like receptor 1 (CMKLR1 ). In some embodiments such methods include treating demyelinating inflammatory disease in a subject by administering an agent that antagonizes the activity of chemokine-like receptor 1 (CMKLR1 ) and/or a CMKLR1 ligand (e.g., chemerin or other endogenous CMKLR1 ligands). Candidate compounds include, without limitation, analogs and variants of 2-(alpha-naphthoyl)ethyltrimethylammonium iodide.
Efficient one-pot selective reduction of esters in β-ketoesters using LiHMDS and lithium aluminium hydride
作者:K. Sivagurunathan、S. Raja Mohamed Kamil、S. Syed Shafi、F. Liakth Ali Khan、R. Venkat Ragavan
DOI:10.1016/j.tetlet.2011.01.030
日期:2011.3
The ester functionality in β-keto esters is selectively reduced in one-pot, first by enolization using LiHMDS and then reduced with lithium aluminium hydride. This method produces β-hydroxyl ketones from the corresponding β-keto esters in high yield.